To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
USA119th CongressHR-9661| House
| Updated: 7/14/2026
Nicholas A. Langworthy
Republican Representative
New York
Cosponsors (1)
Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
USA119th CongressHR-9661| House
| Updated: 7/14/2026
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Nicholas A. Langworthy
Republican Representative
New York
Cosponsors (1)
Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted